Neurotech International (ASX:NTI) YoY EBITDA Growth: 28.57% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neurotech International YoY EBITDA Growth?

Neurotech International ASX:NTI +4.17% YoY EBITDA Growth is 28.57% as of Dec. 2025. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Neurotech International's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 28.57%.

Neurotech International's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.01.

Neurotech International YoY EBITDA Growth Related Terms

Neurotech International YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Neurotech International's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurotech International YoY EBITDA Growth Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.00 -83.33 18.18 -44.44 23.08

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -75.00 0.00 28.57 20.00

Neurotech International YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Neurotech International's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.013--0.009)/ | -0.009 |
=-44.44 %

Neurotech International's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.005--0.007)/ | -0.007 |
=28.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 28.57% mean?
Neurotech International (ASX:NTI) has a YoY EBITDA Growth of 28.57% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Neurotech International and its competitors.
Is Neurotech International's YoY EBITDA Growth too high?
Neurotech International's current YoY EBITDA Growth is 28.57%.
How does Neurotech International's YoY EBITDA Growth compare to VRTX and REGN?
Neurotech International's YoY EBITDA Growth of 28.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Neurotech International and its competitors. Neurotech International's current YoY EBITDA Growth is 28.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (ASX:NTI) has a current YoY EBITDA Growth of 28.57%. The current YoY EBITDA Growth is 28.57%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Neurotech International (ASX:NTI), the current YoY EBITDA Growth is 28.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurotech International Business Description

Address 55 Collins Street, Suite 102, Level 1, Melbourne, VIC, AUS, 3000
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.